Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Dermatol Ther (Heidelb)

Institute and Comprehensive Center Inflammation Medicine, University of Lübeck, Lübeck, Germany.

Published: January 2025

Download full-text PDF	Source
http://dx.doi.org/10.1007/s13555-024-01328-4	DOI Listing

Publication Analysis

correction efficacy

efficacy safety

safety risankizumab

risankizumab patients

patients psoriasis

psoriasis showing

showing suboptimal

suboptimal response

response secukinumab

secukinumab ixekizumab

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!